propafenone has been researched along with Lown-Ganong-Levine Syndrome in 1 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Lown-Ganong-Levine Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a normal QRS complex. In this syndrome, the atrial impulse conducts via the JAMES FIBERS which connect the atrium to BUNDLE OF HIS bypassing the upper ATRIOVENTRICULAR NODE. HEART VENTRICLES are depolarized normally through the His-Purkinje system.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propafenone was administered in doses of 450 and 900 mg/day, during 5-7 days, at which moment another HM and esophageal stimulation were repeated." | 2.68 | [Use-dependence of propafenone. Clinical demonstration of the hypothesis of modulated receptors]. ( González Zuelgaray, J; Labadet, CD; Peralta, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Labadet, CD | 1 |
| Peralta, A | 1 |
| González Zuelgaray, J | 1 |
1 trial available for propafenone and Lown-Ganong-Levine Syndrome
| Article | Year |
|---|---|
[Use-dependence of propafenone. Clinical demonstration of the hypothesis of modulated receptors].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Cardiac Comp | 1995 |